|
|
5-day change | 1st Jan Change | ||
|
0.9100 USD |
-2.19% | -34.25% | -85.44% | |
April 08, 2025 at 10:15 am EDT
© MT Newswires – 2025
|
Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million |
10:15am |
MT |
|
Scienture Announces The Divestiture Of Its Legacy Subsidiaries |
09:32am |
RE |
|
Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders |
Apr. 04 |
RE |
|
Scienture Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Mar. 26 |
CI |
|
Scienture Holdings, Inc. Auditor Raises ‘Going Concern’ Doubt |
Mar. 25 |
CI |
|
Scienture Says US FDA Approves Oral Liquid Formulation of Hypertension Drug Losartan |
Mar. 18 |
MT |
|
Scienture Holdings, Inc. Announces Chief Financial Officer Changes, Effective March 13, 2025 |
Mar. 13 |
CI |
|
Scienture Unit, Summit Biosciences Collaborate to Launch Naloxone Spray for Opioid Overdose Treatment in the US |
Mar. 06 |
MT |
|
Scienture To Commercially Launch Rezenopy |
Mar. 06 |
RE |
|
Scienture Holdings, Inc. Announces Director Resignations |
Jan. 17 |
CI |
|
Scienture Files for Shareholders to Sell Up to 4.3 Million Common Shares |
Dec. 04 |
MT |
|
Scienture Holdings, Inc. announced that it expects to receive $12.222222 million in funding from Arena Business Solutions Global SPC II, Ltd. |
Nov. 21 |
CI |
|
Scienture Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 06 |
CI |
|
Scienture Holdings, Inc. Auditor Raises ‘Going Concern’ Doubt |
24-09-24 |
CI |
|
Scienture Holdings, Inc.(NasdaqCM:SCNX) added to NASDAQ Composite Index |
24-09-23 |
CI |
|
Scienture Holdings, Inc. has Changed its Ticker to SCNX from MEDS |
24-09-23 |
CI |
|
TRxADE HEALTH, Inc. has Changed its Name to Scienture Holdings, Inc |
24-09-23 |
CI |
|
TRxADE Health to Change Name to Scienture Holdings |
24-09-20 |
MT |
|
TRxADE HEALTH, Inc.(NasdaqCM:MEDS) dropped from NASDAQ Composite Index |
24-09-19 |
CI |
|
TRxADE HEALTH, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-28 |
CI |
|
Scienture Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-09 |
CI |
|
Trxade Health, Inc. and Scienture, LLC Announces Executive Changes |
24-08-05 |
CI |
|
TRxADE Health, Scienture Complete Business Combination; TRxADE Shares Jump |
24-07-26 |
MT |
|
Scienture Inc. acquired TRxADE HEALTH, Inc. in a reverse merger transaction in a transaction valued at $103 Million. |
24-07-25 |
CI |
|
Tranche Update on TRxADE HEALTH, Inc.’s Equity Buyback Plan announced on May 28, 2021. |
24-06-26 |
CI |
SCNX: Dynamic Chart
Scienture Holdings, Inc., formerly TRxADE Health, Inc., is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the United States. It operates through Scienture, LLC and Integra Pharma Solutions, LLC. Scienture, LLC is a branded specialty pharmaceutical company. Its assets in development are across therapeutics areas, indications and cater to different market segments. Its products include SCN – 102 (Cardiovascular), SCN – 104 (CNS-Pain), SCN – 105 (CNS), SCN – 106 (Cardiovascular) and SCN – 107 (Pain). Integra Pharma Solutions, LLC is the pharmaceutical supplier of choice for healthcare organizations of all sizes. Its expertise in the distribution of products extends to all healthcare markets including government organizations, hospitals, clinics, and independent pharmacies nationwide.
More about the company
